Pharmacokinetics and bioequivalence study of tetramethylpyrazine phosphate tablets after single-dose administration in healthy Chinese male subjects
Houli Li1, 2, Benjie Wang2, Guiyan Yuan2, Ruichen Guo2
1 Department of Pharmacy, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, and 2 Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan, China
DOI 10.5414/CP203270
Abstract
Background: Tetramethylpyrazine, isolated from <i>Ligusticum wallichii</i> Franch., is widely used for the treatment of cerebrovascular and cardiovascular diseases in China. Objective: To assess and compare the pharmacokinetic characteristics and bioequivalence of two tetramethylpyrazine phosphate (TMPP) tablets in healthy Chinese male subjects. Materials and methods: 20 healthy male subjects were randomly divided into two groups according to a two-period crossover design test. A single oral dose of 200 mg test or reference tablets was given with a 7-day washout period under fasting conditions. Blood samples were taken at scheduled time points, and the concentration of TMPP was measured by LC-MS. Drug And Statistical Software-Version 2.0 was used to calculate the pharmacokinetic parameters and assess bioequivalence of the two formulations. Results: 20 subjects were enrolled in the study, and none dropped out. The main pharmacokinetic parameters of test and reference formulations were as follows: T<sub>1/2</sub> was (1.79 ± 0.82) hours and (1.64 ± 0.52) hours, t<sub>max</sub> was (0.76 ± 0.37) hours and (0.94 ± 0.44) hours, C<sub>max</sub> was (961.14 ± 309.64) ng/mL and (1,059.09 ± 350.69) ng/mL, AUC<sub>0–12h</sub> was (1,744.69 ± 643.49) ng×h/mL and (1,726.32 ± 494.11) ng×h/mL, AUC<sub>0–∞</sub> was (1,756.95 ± 643.63) ng×h/mL and (1,740.16 ± 504.89) ng×h/mL, respectively. The relative bioavailability of TMPP tablets was 102.4 ± 26.0%, and no serious adverse events were reported. Conclusion: This single-dose study in healthy Chinese male fasted subjects showed that the TMPP test and reference tablets were bioequivalent.
Author Details
Authors
Departments
- 1 Department of Pharmacy, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, and
- 2 Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan, China
Address
Prof. Ruichen Guo
Institute of Clinical Pharmacology
Qilu Hospital of Shandong University
107 West Wenhua Road, Jinan 250012, China
Email:
[email protected]
Citation
Houli Li, Benjie Wang, Guiyan Yuan, and Ruichen Guo. Pharmacokinetics and bioequivalence study of tetramethylpyrazine phosphate tablets after single-dose administration in healthy Chinese male subjects
. 2018; 56: 387-392. doi: 10.5414/CP203270.